...
首页> 外文期刊>Transactions of the Royal Society of Tropical Medicine and Hygiene >Dengue seroprevalence: data from the clinical development of a tetravalent dengue vaccine in 14 countries (2005-2014)
【24h】

Dengue seroprevalence: data from the clinical development of a tetravalent dengue vaccine in 14 countries (2005-2014)

机译:登革热血清透视:来自14个国家的四价登革热疫苗的临床开发的数据(2005-2014)

获取原文
获取原文并翻译 | 示例
           

摘要

Dengue seroprevalence data in the literature is limited and the available information is difficult to compare between studies because of the varying survey designs and methods used. We assessed dengue seropositivity across 14 countries using data from 15 trials conducted during the development of a tetravalent dengue vaccine between October 2005 and February 2014. Participants' dengue seropositivity (n=8592) was determined from baseline (before vaccination) serum samples at two centralized laboratories with the plaque reduction neutralization test (PRNT50). Seropositivity rates generally increased with age in endemic settings. Although seropositivity rates varied across geographical areas, between countries, and within countries by region, no major differences were observed for given age groups between the two endemic regions, Latin America and Asia-Pacific. Seropositivity rates were generally stable over time. The proportion of participants who had only experienced primary infection tended to be higher in younger children than adolescents/adults. These results will help inform and guide dengue control strategies in the participating countries.
机译:文献中的登革热血管升迁数据有限,并且由于使用的调查设计和方法不同,研究难以在研究之间进行比较。我们评估了在2005年10月和2014年10月之间开发的四价疫苗中进行的15个审判中的14个国家的登革热血清阳性。参与者的登革热血清阳性(n = 8592)是由两种集中式的基线(疫苗接种前)血清样本中确定实验室用斑块还原中和试验(PRNT50)。血清阳性率通常随着人际环境中的年龄而增加。虽然血液阳性率在各国之间的地理区域,各国之间的地理区域而变化,但在两个地方区域,拉丁美洲和亚太地区之间给予年龄群体没有观察到任何重大差异。随着时间的推移,血清阳性速率通常稳定。在比青少年/成年人的孩子们的比例中,只有经历的原发性感染的参与者的比例往往更高。这些结果将有助于为参与国的登记控制策略提供帮助,并指导登革热控制策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号